Drug Type Monoclonal antibody |
Synonyms B 007 (Shanghai Jiaolian Drug), B-007 (Shanghai Jiaolian Drug) |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Idiopathic Membranous Glomerulonephritis | Phase 3 | CN | 30 Jul 2024 | |
Glomerulonephritis, Membranous | Phase 3 | CN | 16 Jul 2024 | |
Myasthenia Gravis | Phase 3 | CN | 01 Jul 2024 | |
Pemphigus | Phase 3 | CN | 26 Jun 2024 | |
Nephrosis | Phase 1 | CN | 03 Sep 2022 | |
CD20 Positive B-Cell Non-Hodgkin Lymphoma | Phase 1 | CN | 16 Nov 2021 |